InVivoSIM anti-human PD-1 (Nivolumab Biosimilar)

Deng R, Tian R, Li X, et al. ISG12a promotes immunotherapy of HBV-associated hepatocellular carcinoma through blocking TRIM21/AKT/β-catenin/PD-L1 axis. iScience. 2024,27(4):109533. doi: 10.1016/j.isci.2024.109533

Ruggiu M, Guérin MV, Corre B, et al. Anti-PD-1 therapy triggers Tfh cell-dependent IL-4 release to boost CD8 T cell responses in tumor-draining lymph nodes. J Exp Med. 2024,221(4). doi: 10.1084/jem.20232104

Das S, Valton J, Duchateau P, et al. Stromal depletion by TALEN-edited universal hypoimmunogenic FAP-CAR T cells enables infiltration and anti-tumor cytotoxicity of tumor antigen-targeted CAR-T immunotherapy. Front Immunol. 2023,14:1172681. doi: 10.3389/fimmu.2023.1172681

Lam W, Hu R, Liu SH, et al. YIV-906 enhances nuclear factor of activated T-cells (NFAT) activity of T cells and promotes immune checkpoint blockade antibody action and CAR T-cell activity. Front Pharmacol. 2022,13:1095186. doi: 10.3389/fphar.2022.1095186

Qiu H, Zmina PM, Huang AY, et al. Inhibiting Notch1 enhances immunotherapy efficacy in melanoma by preventing Notch1 dependent immune suppressive properties. Cancer Lett. 2018,434:144-151. doi: 10.1016/j.canlet.2018.07.024